Neoplasms

Symptoms and General Pathology

All Conditions

Nutritional and Metabolic Diseases

Gland and Hormone Related Diseases

Eye Diseases

Heart and Blood Diseases

Neoplasm Metastasis

Diabetes Mellitus

Hemorrhage

Diabetic Retinopathy

Retinal Diseases

Vitreous Hemorrhage

Neoplastic Processes

Eye Hemorrhage

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Patients will not receive bevacizumab before nor during vitrectomy

Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy

Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy

1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy

1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy

bevacizumab

Hospital das Clínicas de Ribeirão Preto - USP

Felipe Almeida, MD

The purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.

Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. Bevacizumab (Avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. We believe that preoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by decreasing the amount of abnormal vessels and intraoperative injection could also reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage Secondary to Diabetic Retinopathy

University of Sao Paulo

Hospital das Clínicas de Ribeirão Preto - University of São Paulo

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage	NCT01091896	Vitreous Hemorr...	Bevacizumab bevacizumab	18 Years -	University of Sao Paulo
Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage	NCT01091896	Vitreous Hemorr...	Bevacizumab bevacizumab	18 Years -	University of Sao Paulo

Spots Global Cancer Trial Database for vitreous hemorrhage